Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentra cerrado desde el 19 de junio. La solicitud de ayudas para los Bonos 1, 2 y 4 permanecen abiertos.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
63
resultados
Última actualización
22/07/2025 [07:22:00]
Resumen de: JP2024037794A
To provide a method for measuring an amount of singly or multiply phosphorylated p217+tau protein in a sample, regarding compositions and methods for detecting neurodegeneration.SOLUTION: A method for measuring a p217+ tau peptide in a sample, comprises: (i) contacting the sample with a capture antibody against a p217+ tau epitope to capture the p217+ tau peptide in the sample; and (ii) contacting the captured p217+ tau peptide with at least one of a first detection antibody against an epitope comprising amino acid residues 119 to 126 of a tau protein and a second detection antibody against an epitope comprising amino acid residues 7 to 20 of the tau protein, and measuring at least one of an amount of the p217+ tau peptide and an amount of a long p217+ tau peptide, where amino acid numbering refers to a specific amino acid sequence.SELECTED DRAWING: None
Resumen de: US2025231201A1
Described herein are biological devices and extracts useful for detecting Alzheimer's disease and/or concussions. The biological devices include microbial cells transformed with a DNA construct containing genes for producing β-amyloid precursor protein, microtubule associated protein tau, adipose triglyceride lipase, acyl-CoA dehydrogenase, and O-linked N-acetylglucosamine transferase. In some instances, the biological devices also include a gene for enhanced green fluorescent protein. Methods for using the devices to diagnose or detect Alzheimer's disease and/or concussions are also provided herein.
Resumen de: US2025231178A1
The present disclosure relates to a method for determining a risk of development or risk of presence of Alzheimer's disease in a human subject comprising analyzing an activity of a PIEZO1 receptor. The disclosure also relates to a kit for determining a risk of development or risk of presence of Alzheimer's disease according to the present method. The disclosure also relates to an in vitro use of a PIEZO1 receptor as a biomarker and determination of intracellular calcium level as a biomarker for determining a risk of development or risk of presence of Alzheimer's disease in a human subject.
Resumen de: WO2025148411A1
A protein antigen for Alzheimer's disease detection comprises at least any two of DOC2A, LGALS1, KDM4D, and ADARB1 proteins at the same time, can be used for early detection or diagnosis of Alzheimer's disease, and is suitable for risk assessment and prediction of before the onset of Alzheimer's disease; moreover, the protein antigen can distinguish Alzheimer's disease from other types of dementia, and can be further prepared into a related reagent or kit according to requirements.
Resumen de: AU2025204747A1
The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer’s disease. The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease. un u n h e i n v e n t i o n r e l a t e s t o m e t h o d s a n d c o m p o s i t i o n s f o r d e v e l o p i n g b a s a l f o r e b r a i n c h o l i n e r g i c n e u r o n s ( s ) f r o m s t e m c e l l s , a n d i n p a r t i c u l a r , s h a v i n g r e p a i r e d e l e c t r o p h y s i o l o g i c a l d e f e c t s r e l a t i n g t o o n e o r m o r e m u t a t i o n s i n , a n d t o t h e u s e o f s u c h s i n c e l l - b a s e d t h e r a p i e s t o t r e a t l z h e i m e r ' s d i s e a s e
Resumen de: MX2024013690A
The present disclosure provides devices for the detection and/or quantification of neurotoxic amyloid-type protein aggregates, comprising a doxycycline derivative immobilized on an appropriate surface, as well as electrochemical and immunochemical methods associated to the use of such devices.
Resumen de: WO2024052650A1
The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and/or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and/or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.
Resumen de: CN119866443A
Described herein are methods for detecting conformational diseases, aging, and proteinopathies by measuring the presence of b-isox precipitates and the level of b-isox capture proteins in biological fluids of healthy individuals and patients. The studies have identified additional biomarkers that make it possible to detect biomarkers by adding or not adding isoxazole to the obtained biological fluid sample, thereby making it possible to detect, diagnose or treat human diseases in a human subject. Diagnosis of disease using b-isox and/or biomarkers becomes possible.
Resumen de: US2025224408A1
Provided herein are methods, compositions, and systems for diagnosing, assessing the likelihood of Alzheimer's disease, and assessing the rate of progression of Alzheimer's disease comprising assaying biofluid samples and identifying from the biofluid samples the presence/abundance of one or more biomarkers. Also provided herein are methods of assessing the likelihood of dementia progression or the rate of dementia progression comprising assaying biofluid samples and identifying from the biofluid samples the presence/abundance of one or more biomarkers.
Resumen de: US2025222034A1
A method of generating MSC-derived exosome populations may include collecting MSC containing material from living tissue, separating desired mononuclear cells from granulocytes, culturing to multiply the cells, separation of desired cells for further multiplication by washing non-adherent cells and culturing adherent cells, repeating as necessary to obtain a suitably pure population of MSCs, culturing the MSCs in culture media containing negative/healing active cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10) and multifunctional cytokine TGF-ß, and isolating the MSC-derived exosome populations. Diverse MSC-derived exosome populations may be generated by altering the cytokine composition of the culture media. The MSC-derived exosome populations may be screened for effectiveness in treatment of Long Covid using in vitro, in vivo, and pre-clinical testing utilizing model organisms. The exosomes may be administered nasally. Successful MSC-derived exosome populations may be further subjected to patient trials to establish efficacy in treatment of Long Covid via nasal administration of the MSC-derived exosome populations to human subjects. Similar methodologies may be employed to establish efficacy of the MSC-derived exosome populations for treatment of other diseases and conditions related to the central nervous system, spinal cord injury, or neurological diseases, such as Alzheimer disease.
Resumen de: EP4582144A2
The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
Resumen de: US2025215504A1
The present invention includes a method for analyzing tRNAHisGTG fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat and/or prevent a disease or condition, disease recurrence, or disease progression comprises characterizing the identity of tRNAHisGTG fragments. The invention further includes diagnosing, identifying or monitoring a disease or condition, a panel of engineered oligonucleotides, a kit for a high-throughput assay, and a method and system for identifying tRNAHisGTG fragments.
Resumen de: WO2025138512A1
Provided are an apolipoprotein E detection reagent and the use thereof. The reagent comprises at least one of an ApoE2 protein detection reagent, an ApoE3 protein detection reagent and an ApoE4 protein detection reagent. One of a capture antibody and a detection antibody used for detecting ApoE2 protein or ApoE4 protein is a specific monoclonal antibody, and the capture antibody and the detection antibody used for detecting ApoE3 are both specific monoclonal antibodies. Genotyping of ApoE and quantitative detection of different genotypes of proteins are performed on the basis of an immunological detection method. The detection method has the advantages of being simple, easy to operate, short in time and cheap. A genotype detection result is highly consistent with a fluorescence PCR result. Genotyping of ApoE (6 types) can be performed, which is used to replace the nucleic acid detection and guide medication, and clarify the correlation of the ApoE4 genotype homozygosity/heterozygosity and the protein concentration of ApoE4 with AD.
Resumen de: CN119744269A
Provided herein are antibodies or fragments thereof that specifically bind to the microtubule binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting MTBR species in blood or cerebrospinal fluid, as well as the use of such detection for diagnosing, prognosing or staging pathological characteristics and/or clinical symptoms of tauopathy, and selecting a treatment suitable for a given disease stage.
Resumen de: WO2024042210A1
The invention relates to methods and uses of cell free histone H3 isoforms H3.1, H3.2, H3t and/or H3.3 (or cell free nucleosomes containing said isoforms) of determining the origin of a cell free histone or cell free nucleosome in a body fluid sample as originating from a dividing or non-dividing cell.
Resumen de: AU2023329158A1
The invention relates to methods of detecting, diagnosing or monitoring an inflammatory condition of the central nervous system, in particular by detecting or measuring neutrophil extracellular traps, extracellular traps and/or cell free nucleosomes.
Resumen de: EP4578872A1
Provided is an anti-TREM2 single-domain antibody, consisting of heavy chains comprising CDR1 represented by any one of SEQ ID NOs: 34-40, CDR2 represented by any one of SEQ ID NOs: 41-45, and CDR3 represented by any one of SEQ ID NOs: 46-50. The single-domain antibody has good affinity with TREM2.
Resumen de: AU2025204068A1
Abstract Provided herein are sulfopropanoic acid derivatives or pharmaceutically acceptable salts thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.
Resumen de: WO2025137077A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Resumen de: US2025208143A1
Disclosed are fragments of p53 peptide (P1) and their use in the diagnosis and/or prognosis of Alzheimer's disease (AD) in a biological sample. The invention provides a method based on mass spectrometry analysis for the diagnosis of Alzheimer's disease at the pre-clinical and prodromal stages of the disease and for the prognosis of cognitive decline in a subject, by quantitating the levels of one or more p53 peptide fragments in a biological sample of a subject.
Resumen de: WO2025137532A1
Disclosed herein are methods of measuring amyloid β protofibril levels in biological samples. Methods disclosed herein may detect amyloid β protofibril at femtomolar concentrations and selectively measure protofibril as compared to amyloid β monomers.
Resumen de: WO2025137359A1
Among the various aspects of the present disclosure is the provision of assay methods to identify diseases associated with orexin levels. The present teachings include methods to quantify an orexin concentration in a fluid sample, such as a cerebrospinal fluid sample, and identifying and treating diseases, including but not limited to narcolepsy and Alzheimer's disease, from the orexin concentration.
Resumen de: US2025208135A1
The present invention provides a method for early detection or diagnosis of a neurodegenerative disease, disorder, or condition in a subject at risk of developing or suspected of having the neurodegenerative disease, disorder, or condition, the method comprising measuring in a blood sample obtained from the subject or a fraction thereof the levels of at least one biomarker selected from CD38+ peripheral blood mononuclear cells (PBMCs), trigonelline, GLUT1 expression in CD4+ T cells, Th2, Th2/Th1 ratio, naïve T cells, adenosine, allose, and HLA-DR T cells, as well as related methods and kits.
Resumen de: KR20250094349A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 TMEM266(Transmembrane protein 266) 단백질의 발현 수준이 11배 높게 나타나는 것을 확인함에 따라 TMEM266(Transmembrane protein 266) 단백질 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094348A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 갈렉틴-7(Galectin-7) 단백질의 발현 수준이 11배 높게 나타나는 것을 확인함에 따라 갈렉틴-7(Galectin-7) 단백질 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094344A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 호르네린(Hornerin) 단백질의 발현 수준이 98배 높게 나타나는 것을 확인함에 따라 호르네린(Hornerin) 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094347A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 BCAM(Basal cell adhesion molecule) 단백질의 발현 수준이 13배 높게 나타나는 것을 확인함에 따라 BCAM(Basal cell adhesion molecule) 단백질 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094345A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 판테테이나제(Pantetheinase) 단백질의 발현 수준이 48배 높게 나타나는 것을 확인함에 따라 판테테이나제(Pantetheinase) 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094346A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 Rab2A(Ras-related protein Rab-2A) 단백질의 발현 수준이 15배 높게 나타나는 것을 확인함에 따라 Rab2A(Ras-related protein Rab-2A) 단백질 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: PH12021552938A1
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: AU2023406056A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: WO2024052650A1
The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and/or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and/or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.
Resumen de: WO2025123283A1
The use of a reagent, which detects changes in the concentration or number of immune cells and immune factors in the peripheral circulatory system and cerebrospinal fluid, in the preparation of a diagnostic tool or a therapeutic tool for diagnosing or monitoring Alzheimer's disease. A method for diagnosing or monitoring Alzheimer's disease, in which a reagent for detecting immune cells and immune factors in the peripheral circulatory system and cerebrospinal fluid is used to detect changes in the concentration or number of the immune cells and immune factors in the peripheral circulatory system and cerebrospinal fluid. A method for treating Alzheimer's disease, in which immune cells and immune factors in the peripheral circulatory system and cerebrospinal fluid are taken as targets for administration so as to reduce or decrease the concentration or number of the immune cells and immune factors.
Resumen de: WO2025125705A1
An in vitro procedure for diagnosing or determining the risk of a person developing Alzheimer's disease (AD), said procedure detecting and quantifying the expression products of the LMNA gene (SEQ. ID: No. 3): lamin A protein (SEQ. ID: No. 1) and its precursor prelamin A (SEQ. ID: No. 2), in a sample of peripheral nerve or smooth muscle.
Resumen de: WO2025128726A1
Disclosed herein are methods for analyzing oligomeric protein structures by mass spectrometry. The method includes providing a sample having one or more oligomers; producing, with an ion source, ions of the sample, each of the ions having a mass-to-charge (m z) ratio; detecting a multiplicity of ions generated with a current detector; determining ion masses for each of the multiplicity of ions detected with the current detector with a mass analyzer; generating a mass-domain spectrum from the ion masses with the mass-analyzer, the mass-domain spectrum having one or more mass-domain peaks; and determining one or more metrics capturing the mass heterogeneity and/or mass abundance of oligomers. Methods for diagnosing a subject, assessing treatment efficacy, and assessing treatment efficacy are also provided.
Resumen de: WO2025123398A1
An Alzheimer's disease biomarker based on a brain metabolite and a use thereof. The biomarker comprises any one or a combination of at least two of palmitic acid, DHA, gallic acid, 11Z,14Z,17Z-eicosatrienoic acid, glycodeoxycholic acid, palmitoleic acid, linoleic acid, erucic acid, petroselinic acid, and arachidonic acid. The level of a metabolite is detected to assist in early diagnosis of the Alzheimer's disease, thus facilitating rapid detection; in addition, the present invention has the characteristics of timeliness, convenience, high specificity and high sensitivity.
Resumen de: EP4571315A1
A use of a new highly toxic amyloid oligomer Apo*3F as a target for diagnosing Alzheimer's disease (AD) in the early stage and the middle-late stage and mild cognitive impairment (MCI) caused by AD. The Aβo*3F specifically binds to an antibody 3F and is present in cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and patients with MCI caused by AD, and the levels show highly significant differences in CSF, blood and/or brain tissue of AD patients, MCI patients and healthy elderly persons. In addition, the Apo*3F is an ultra-highly toxic oligomer, is the most important toxic component in an Aβ oligomer mixture, has a strong pathogenic effect, and plays a key role in the occurrence and development of AD.
Resumen de: EP4570823A1
The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of the antibody W20. Compared with the antibody W20, the improved form of the antibody W20 has a significantly improved affinity to AβOs, and can more significantly inhibit the aggregation of Aβ and the AβOs-induced toxicity of nerve cells, more effectively improve the cognition and memory functions of an Alzheimer's disease model mouse, and reduce pathological changes in the brain of the mouse. The improved form of the antibody can specifically bind to oligomers of an amyloid-β, α-synuclein, mHTT and SOD 1, can inhibit the aggregation and cytotoxicity of various amyloids, and has a better potential for treating various amyloid diseases, such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, than the antibody W20. The improved form of the antibody can specifically bind to a highly toxic amyloid protein oligomer Aβo*3F, and has a better AD diagnosis value. The amino acid sequence of the antibody W20 is as shown in SEQ ID NO: 1.
Resumen de: AU2023357033A1
The present disclosure generally relates to the surprising discovery that subjects likely to respond to treatment with an 11β-HSD1 inhibitor can be selected for treatment based on a comparison between a baseline level of a tau protein in the subject, and a reference level of the tau protein.
Resumen de: US2025191903A1
Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: US2025189536A1
The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (Aβ) peptides and methods of use thereof.
Resumen de: US2025189543A1
A method for quantifying active orexin A in a specimen, comprising: a step of contacting the specimen with a monoclonal antibody that recognizes the C-terminal side of orexin A to separate orexin A species; a step of digesting the separated orexin A species with a protease to obtain a peptide consisting of an amino acid sequence of SEQ ID NO: 1; and a step of performing mass spectrometry on the peptide.
Resumen de: US2025189517A1
A solution is described for preserving cells and/or extra cellular components in naturally expressed bodily fluids (e.g. saliva, sputum, urine) for further downstream analysis and/or for diagnosis of a medical condition. The solution may be hypertonic with respect to blood. Techniques are described for enriching cells from a sample of a naturally expressed bodily fluid, and/or for analysis, e.g. to diagnose medical conditions such as cancer, obesity, infections, autism, Alzheimer disease, hetotological disorders, cardiovascular disease or disorders, diabetes, vulnerable plack, LTBI, HIV infection, COPD, ACQS.
Resumen de: EP4567427A1
A method for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases, comprising determining the level of TPK1 protein in a sample from a subject, wherein a decrease in the level of TPK1 protein compared to a reference value indicates that the subject has Alzheimer's disease. Methods, compositions, test strips, test cards and/or kits for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases by detecting a biomarker, wherein the methods, compositions, test strips, test cards and/or kits can specifically diagnose Alzheimer's disease.
Resumen de: US2022373562A1
The present disclosure relates generally to a sensor chip and methods for the detection of an analyte. In particular, the disclosure relates to a sensor chip for detecting an analyte in a subject suffering from a neurodegenerative disease. The sensor chip comprises a conductive layer on a membrane support layer, wherein a plurality of apertures extend through the conductive layer and the membrane support layer and are arranged such that illumination of the conductive layer and/or the membrane support layer produces a surface plasmon resonance.
Resumen de: AU2023356443A1
Provided is a protein marker Nell-1, which is present in a person's blood sample in an amount that is correlated with neurodegenerative disorders such as Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), and Parkinson's Disease (PD). Corresponding diagnostic and treatment methods for these neurodegenerative disorders as well as kits for diagnosing or treating the neurodegenerative disorders are also provided.
Resumen de: US2025179489A1
An optimized method based on a dual promoter vector of the reprogramming factors combined with knock-down of the neural silencing complex RESTi to convert adult fibroblasts into induced neurons (iNs). We have also designed and cloned vector constructs of which some include all these components which allows for a one-step method to efficiently reprogram dermal fibroblasts including those obtained from elderly individuals. The single vector system can be used to obtain iNs of high yield and purity from biopsies from aged individuals with a range of familial and sporadic neurodegenerative disorders including Parkinson's, Huntington's as well as Alzheimer's disease.
Resumen de: WO2025113065A1
A method for detection of a free modified nucleic acid metabolite is used to determine a modification on a nucleic acid molecule. A system is used for implementing the method.
Resumen de: WO2025113506A1
The present invention relates to the field of biomedicine. Provided are a marker that can be used for early diagnosis of Alzheimer's disease, and the use thereof. Specifically provided is a marker for early diagnosis of Alzheimer's disease. The marker is a Maf1 gene or the protein thereof. High expression of the Maf1 gene or the protein thereof in neuronal cells indicates that a subject is at high risk of developing Alzheimer's disease. The method provides a new diagnostic and therapeutic target for AD.
Resumen de: WO2024026413A2
Methods, systems and kits useful for the detection and diagnosis of neurodegenerative diseases including Alzheimer's Disease (AD)- and early-stage Parkinson's Disease-related pathology, and methods of preparing labeled immunocomplexes useful for detecting AD- and PD-related pathology are provided.
Resumen de: AU2023334129A1
The invention relates to identification of an intron-retaining Tau splicing isoform as a novel Alzheimer's disease biomarker. Provided herein are polypeptides to generate binding molecules, such as antibodies specific for the Tau11i isoform, oligonucleotides and antibodies for use in methods for detecting the Tau11i isoform in a sample and methods for use in diagnosis for Alzheimer's disease.
Resumen de: CN118388648A
The invention discloses an anti-human PD-L1 antibody based on a fully human antibody mouse or an antigen binding fragment thereof, a nucleic acid molecule for coding the antibody or the antigen binding fragment, and a preparation method and application of the antibody or the antigen binding fragment. The anti-human PD-L1 antibody or the antigen binding fragment thereof is a fully humanized sequence, has good specificity and affinity to PD-L1, and can effectively promote secretion of IL2 and IFN gamma of T cells. And the immunogenicity is lower. The invention further relates to a pharmaceutical composition containing the antibody or the antigen binding fragment thereof and application of the antibody or the antigen binding fragment thereof in preparation of drugs for preventing and/or treating PD-L1 related diseases.
Resumen de: US2025060376A1
The present application relates to a digested DDIT4L product as a diagnostic marker for Alzheimer's disease, and use thereof in diagnosing Alzheimer's disease. In particular, the present application relates to use of a substance for detecting a digested intron retention (DIR) product encoding DNA-damage-inducible transcript 4 like (DDIT4L) in a sample of a subject in preparing a product for diagnosing Alzheimer's disease or a mild cognitive disorder and/or assessing (e.g., grading or staging) cognitive disorder progression, a related product thereof, and a method for screening a medicament using the DIR product.
Resumen de: CN118388648A
The invention discloses an anti-human PD-L1 antibody based on a fully human antibody mouse or an antigen binding fragment thereof, a nucleic acid molecule for coding the antibody or the antigen binding fragment, and a preparation method and application of the antibody or the antigen binding fragment. The anti-human PD-L1 antibody or the antigen binding fragment thereof is a fully humanized sequence, has good specificity and affinity to PD-L1, and can effectively promote secretion of IL2 and IFN gamma of T cells. And the immunogenicity is lower. The invention further relates to a pharmaceutical composition containing the antibody or the antigen binding fragment thereof and application of the antibody or the antigen binding fragment thereof in preparation of drugs for preventing and/or treating PD-L1 related diseases.
Resumen de: WO2025113065A1
A method for detection of a free modified nucleic acid metabolite is used to determine a modification on a nucleic acid molecule. A system is used for implementing the method.
Resumen de: AU2023347307A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: US2025172555A1
The present invention relates to a lateral flow test device capable of detecting the presence or absence of unfolded p53 in a liquid sample, such as a blood sample. Also provided are methods of using such a device for quantitative or qualitative measurement of U-p53 in a liquid sample. Detection of the presence of this analyte in the sample identifies if the subject has a risk to develop Alzheimer's Disease, and also is useful to confirm a diagnosis of Alzheimer's disease.
Resumen de: US2025170124A1
This disclosure provides compounds, pharmaceutical compositions, imaging compositions and methods useful for the diagnosis and/or treatment of neurodegenerative diseases. In particular, this disclosure provides compounds, including radiolabeled compounds, compositions, and methods useful for the diagnosis and/or treatment of neurodegenerative diseases associated with a-synuclein aggregation, such as Parkinson's disease, dementia with Lewy bodies, multiple systems atrophy or prodromal REM sleep behavior disorder.
Resumen de: US2025172549A1
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Resumen de: KR20250074777A
본 발명은 포르피로모나스 진지발리스 LPS에 특이적으로 결합하는 1T2A5 항체 및 이의 용도에 관한 것으로서, 더욱 상세하게, 본 발명은 특정 서열의 중쇄 CDR 및 경쇄 CDR을 포함하는 포르피로모나스 진지발리스 LPS에 특이적으로 결합하는 1T2A5 항체 또는 이의 항원 결합 단편에 대한 것이다. 상기 항체는 포르피로모나스 진지발리스 균주의 검출 및 치주 질환 진단에 유용하게 활용될 수 있을 것으로 예상된다.
Resumen de: KR20250074778A
본 발명은 포르피로모나스 진지발리스 LPS에 특이적으로 결합하는 1T2G1 항체 및 이의 용도에 관한 것으로서, 더욱 상세하게, 본 발명은 특정 서열의 중쇄 CDR 및 경쇄 CDR을 포함하는 포르피로모나스 진지발리스 LPS에 특이적으로 결합하는 1T2G1 항체 또는 이의 항원 결합 단편에 대한 것이다. 상기 항체는 포르피로모나스 진지발리스 균주의 검출 및 치주 질환 진단에 유용하게 활용될 수 있을 것으로 예상된다.
Resumen de: AU2023329330A1
Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Nº publicación: JP2025081355A 27/05/2025
Solicitante:
イーライリリーアンドカンパニー
Resumen de: US2024141033A1
The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
BOPI
Sede Electrónica
